News

Article

FDA Publishes Compounding Guidance on the Evaluation of Bulk Drug Substances

The draft guidance addresses the agency’s policy on evaluating bulk drug substances in drug compounding.

On March 23, 2018, FDA released draft guidance on drug compounding as part of its implementation of the Drug Quality and Security Act and section 503B of the Federal Food, Drug, and Cosmetic (FD&C) Act. The new draft guidance details the agency’s policy for evaluating bulk drug substances in compounding by outsourcing facilities registered under section 503B of the FD&C Act.

The guidance addresses the agency’s policies for developing bulk lists, including the definition of “bulk drug substances for which there is a clinical need.” Factors and processes used by the agency to evaluate bulk drug substances are also discussed.

“Today’s draft guidance is a significant milestone in our work to implement that compounding priorities plan … As the agency further refines what we intend our policies to be on this important topic, we know that stakeholders will, through the public comment process, bring competing concerns to our attention,” FDA Commissioner Scott Gottlieb, MD, stated in a press release

Source: FDA

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More